Latest News

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ:EXAS) today announced that Tufts Health Plan, with more than 1 million members across Massachusetts and Rhode Island, will cover Cologuard as a colon cancer screening test effective March 15, 2015. Cologuard is the first and only FDA-approved, noninvasive stool-based DNA (sDNA) colorectal cancer screening...Read more

First and only FDA-approved noninvasive stool DNA screening test for colorectal cancer MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced Wheaton Franciscan Healthcare is the first healthcare system in Milwaukee to offer Cologuard®, the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Cologuard makes it easy for average...Read more

1 in 3 is not getting screened for colon cancer. Let's bring everyone out of hiding and in to get screened. Join us on Be Seen, Get Screened to help spread the word.

Exact Sciences Laboratories is dedicated to delivering the most accurate results and providing physicians and patients with world-class service.